Research Progress on the Mechanism of Regulatory T Cells in Tumor Microenvironment of Diffuse Large B-cell Lymphoma

Jun HE; Xuezhong GU; Yating LIN; Fan LI

doi:10.12259/j.issn.2095-610X.S20230607

Volume 44 Issue 6

Jun. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(6): 150-154

Jun HE, Xuezhong GU, Yating LIN, Fan LI. Research Progress on the Mechanism of Regulatory T Cells in Tumor Microenvironment of Diffuse Large B-cell Lymphoma[J]. Journal of Kunming Medical University, 2023, 44(6): 150-154. doi: 10.12259/j.issn.2095-610X.S20230607

Citation:

Jun HE, Xuezhong GU, Yating LIN, Fan LI. Research Progress on the Mechanism of Regulatory T Cells in Tumor Microenvironment of Diffuse Large B-cell Lymphoma[J]. Journal of Kunming Medical University, 2023, 44(6): 150-154. doi: 10.12259/j.issn.2095-610X.S20230607

Citation:

PDF( 545 KB)

Research Progress on the Mechanism of Regulatory T Cells in Tumor Microenvironment of Diffuse Large B-cell Lymphoma

doi: 10.12259/j.issn.2095-610X.S20230607

Jun HE¹,
Xuezhong GU^{1, 2
,
,},
Yating LIN¹,
Fan LI¹

1.
Dept. of Hematology，The Affiliated Hospital of Kunming University of Science and Technology/The First People’s Hospital of Yunnan Province
2.
Yunnan Provinccial Clinical Research Center for Hematologic Disease，Yunnan Province Clinical Center for Hematologic Diseases，Kunming Yunnan 650032，China

Received Date: 2023-04-15
Available Online: 2023-06-16
Publish Date: 2023-06-25

Abstract

Abstract

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. At present, CD20 monoclonal antibody combined with chemotherapy has increased the response rate. However, some people still have poor efficacy or even drug resistance, and new drugs are still needed to improve the response rate. Regulatory T cells play an important role in immune regulation via coordinating cellular and molecular networks in tumor microenvironment in diffuse large B-cell lymphoma, and mediating local immunosuppression, consequently promoting tumor cell proliferation and migration. Therefore, it is promising to target the treatment of diffuse large B-cell lymphoma. This article reviews the mechanisms of regulatory T cells in the diffuse large B-cell lymphoma microenvironment.
- Diffuse large B-cell lymphoma,
- Regulatory T cells,
- Tumor microenvironment

FullText(HTML)

References(32)

References

[1]	Liu Y,Zhang L,Wang B,et al. Requirement for POH1 in differentiation and maintenance of regulatory T cells[J]. Cell Death Differ,2019,26(4):751-762. doi: 10.1038/s41418-018-0162-z
[2]	Shin H J,Kim D Y,Chung J,et al. Prognostic impact of peripheral blood T-cell subsets at the time of diagnosis on survival in patients with diffuse large B-cell lymphoma[J]. Acta Haematol,2021,144(4):427-437. doi: 10.1159/000510912
[3]	Peng F,Qin Y,Mu S,et al. Prognostic role of regulatory T cells in lymphoma: A systematic review and meta-analysis[J]. J Cancer Res Clin Oncol,2020,146(12):3123-3135. doi: 10.1007/s00432-020-03398-1
[4]	Carreras J,Lopez-Guillermo A,Kikuti Y Y,et al. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation[J]. J Clin Exp Hematop,2019,59(1):1-16. doi: 10.3960/jslrt.19003
[5]	Jiménez-Cortegana C,Palazón-Carrión N,Martin Garcia-Sancho A,et al. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial[J]. J Immunother Cancer,2021,9(6):e002323. doi: 10.1136/jitc-2020-002323
[6]	Xu T,Chai J,Wang K,et al. Tumor immune microenvironment components and checkpoint molecules in anaplastic variant of diffuse large B-cell lymphoma[J]. Front Oncol,2021,11:638154. doi: 10.3389/fonc.2021.638154
[7]	Saleh R,Elkord E. FoxP3⁺ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets[J]. Cancer Lett,2020,490:174-185. doi: 10.1016/j.canlet.2020.07.022
[8]	Stirm K,Leary P,Bertram K,et al. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma[J]. Oncoimmunology,2021,10(1):2003533. doi: 10.1080/2162402X.2021.2003533
[9]	Najafi M,Farhood B,Mortezaee K. Contribution of regulatory T cells to cancer: A review[J]. J Cell Physiol,2019,234(6):7983-7993. doi: 10.1002/jcp.27553
[10]	Lainé A,Labiad O,Hernandez-Vargas H,et al. Regulatory T cells promote cancer immune-escape through integrin αvβ8-mediated TGF-β activation[J]. Nat Commun,2021,12(1):6228. doi: 10.1038/s41467-021-26352-2
[11]	Arima H,Nishikori M,Otsuka Y,et al. B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33[J]. Blood Adv,2018,2(18):2282-2295. doi: 10.1182/bloodadvances.2018019919
[12]	Whiteside TL. Human regulatory T cells (Treg) and their response to cancer[J]. Expert Rev Precis Med Drug Dev,2019,4(4):215-228. doi: 10.1080/23808993.2019.1634471
[13]	Feng P,Yang Q,Luo L,et al. The kinase PDK1 regulates regulatory T cell survival via controlling redox homeostasis[J]. Theranostics,2021,11(19):9503-9518. doi: 10.7150/thno.63992
[14]	Okuzono Y,Muraki Y,Sato S. TNFR2 pathways are fully active in cancer regulatory T cells[J]. Biosci Biotechnol Biochem,2022,86(3):351-361. doi: 10.1093/bbb/zbab226
[15]	Dehghani M,Shokrgozar N,Ramzi M,et al. The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL)[J]. Cancer Immunol Immunother,2021,70(10):2961-2969. doi: 10.1007/s00262-021-02889-5
[16]	Göschl L,Scheinecker C,Bonelli M. Treg cells in autoimmunity: from identification to Treg-based therapies[J]. Semin Immunopathol,2019,41(3):301-314. doi: 10.1007/s00281-019-00741-8
[17]	Chen Y,Li M,Cao J,et al. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression[J]. Open Life Sci,2021,16(1):909-919. doi: 10.1515/biol-2021-0094
[18]	Zhong W,Liu X,Zhu Z,et al. High levels of Tim-3⁺Foxp3⁺Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients[J]. Int Immunopharmacol,2021,96:107662. doi: 10.1016/j.intimp.2021.107662
[19]	刘紫嫣,张健,胡雅彬,等. 滤泡调节性T细胞在病毒感染与疫苗免疫中的作用及机制研究进展[J]. 中华实验和临床病毒学杂志,2021,35(1):116-120. doi: 10.3760/cma.j.cn112866-20200924-00254
[20]	Dehghani M,Kalani M,Golmoghaddam H,et al. Aberrant peripheral blood CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma[J]. Cancer Immunol Immunother,2020,69(9):1917-1928. doi: 10.1007/s00262-020-02591-y
[21]	Lozano T,Conde E,Martín-Otal C,et al. TCR-induced FOXP3 expression by CD8⁺ T cells impairs their anti-tumor activity[J]. Cancer Lett,2022,528:45-58. doi: 10.1016/j.canlet.2021.12.030
[22]	Lužnik Z,Anchouche S,Dana R,et al. Regulatory T cells in angiogenesis[J]. J Immunol,2020,205(10):2557-2565. doi: 10.4049/jimmunol.2000574
[23]	Cioroianu A I,Stinga P I,Sticlaru L,et al. Tumor microenvironment in diffuse large B-cell lymphoma: Role and prognosis[J]. Anal Cell Pathol (Amst),2019,2019:8586354.
[24]	Shen R,Xu P P,Wang N,et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma[J]. Clin Transl Med,2020,10(7):e221.
[25]	van Bruggen J A C,Martens A W J,Tonino S H,et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma[J]. Cancers (Basel),2020,12(12):3837. doi: 10.3390/cancers12123837
[26]	包芳,万文丽,朱明霞,等. 初发弥漫大B细胞淋巴瘤外周血Treg绝对数减少与不良预后的相关性[J]. 中国实验血液学杂志,2021,29(1):91-97. doi: 10.19746/j.cnki.issn1009-2137.2021.01.015
[27]	Chang C,Chen Y P,Medeiros L J,et al. Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2021,62(1):76-85. doi: 10.1080/10428194.2020.1817438
[28]	Gao R,Shi G P,Wang J. Functional diversities of regulatory T cells in the context of cancer immunotherapy[J]. Front Immunol,2022,13:833667. doi: 10.3389/fimmu.2022.833667
[29]	Jorapur A,Marshall LA,Jacobson S,et al. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22[J]. PLoS Pathog,2022,18(1):e1010200. doi: 10.1371/journal.ppat.1010200
[30]	Beheshti S A,Shamsasenjan K,Ahmadi M,et al. CAR Treg: A new approach in the treatment of autoimmune diseases[J]. Int Immunopharmacol,2022,102:108409. doi: 10.1016/j.intimp.2021.108409
[31]	Wagner J C,Tang Q. CAR-tregs as a strategy for inducing graft tolerance[J]. Curr Transplant Rep,2020,7(3):205-214. doi: 10.1007/s40472-020-00285-z
[32]	Rana J,Biswas M. Regulatory T cell therapy:Current and future design perspectivs[J]. Cell Immunol,2020,356:104193. doi: 10.1016/j.cellimm.2020.104193

Relative Articles(20)

Relative Articles

[1]	Yan WANG, Rong DING, Lvling ZHANG, Ruohua WANG, Xiaoling ZHAO, Na MA. Efficacy of Blood Transfusion Combined with Chemoradiotherapy in Patients with Colorectal Cancer and its Effect on Tumor Markers and T Lymphocyte Levels. Journal of Kunming Medical University, 2022, 43(8): 61-65. doi: 10.12259/j.issn.2095-610X.S20220809
[2]	Kun ZHAO, Yun XIAO, Chun YANG, Zhiling YAN, Minna DONG, Bingquan XIANG, Mingyao XIAO. Protective Effect of Interleukin-4 in Lipopolysaccharide-induced Acute Lung Injury Models. Journal of Kunming Medical University, 2022, 43(8): 41-46. doi: 10.12259/j.issn.2095-610X.S20220805
[3]	Guo-yi LIU, Qing-qing ZHAO, Yan WU, Shan-shan LI, Lian-mei ZHONG, Jia GENG. Effect and Mechanism of Puerarin on Experimental Autoimmune Encephalomyelitis in Mice. Journal of Kunming Medical University, 2021, 42(4): 1-7. doi: 10.12259/j.issn.2095-610X.S20210401
[4]	Xie Wei , Zhao Chuan , Wang Rong , Wang Wen Ping , Tu Hong . . Journal of Kunming Medical University, 2020, 41(02): 82-86.
[5]	Yu Chao Jun , Zhao Qian Hao , Zhao Ning Hui . . Journal of Kunming Medical University, 2020, 41(07): 11-16.
[6]	Qi Xiao , Zhong Zhao Ming , Sun Chuan Zheng . . Journal of Kunming Medical University, 2020, 41(05): 140-144.
[7]	Huang Ying , Xu Kun Jing , Pu Dong , Li Xiao Fei , Chen Hai Yun , Wu Yan , Wang Li Hua , Li Wen Ming , Luo Yun , He Hua . . Journal of Kunming Medical University, 2019, 40(02): 116-122.
[8]	Long Jun Jun , Li Lan . . Journal of Kunming Medical University, 2019, 40(11): 152-155.
[9]	Huang Ying , Liu Yi Han , Li Cheng Ping , Wu Kun , Zeng Yun . The Expression and Significance of IL-17 and IL-23 in Patients with B-cell non-Hodgkin Lymphoma Treated by RCHOP. Journal of Kunming Medical University, 2017, 38(08): 67-72.
[10]	Huang Ying , Liu Yi Han , Li Cheng Ping , Wu Kun , Zeng Yun . Expression of IL-17 and IL-23 in Patients with B-cell non-HodgkinLymphoma Treated by RCHOP. Journal of Kunming Medical University, 2016, 37(12): 76-81.
[11]	Nie Bo . Clinical Characteristic of 34 Patients with Extranodal Nasal Type NK/T-Cell Lymphoma. Journal of Kunming Medical University,
[12]	Ren Chao Feng . Cuture of Regulatory T Cells and the Changes of Immune Factors in COPD Rats after Venous injection of Regulatory T Cells. Journal of Kunming Medical University,
[13]	Jiang Yan . The Relationship of Regulatory T Cells and Senile Osteoporosis. Journal of Kunming Medical University,
[14]	Du Kai . . Journal of Kunming Medical University,
[15]	Lu Ping . . Journal of Kunming Medical University,
[16]	Yuan Yong . . Journal of Kunming Medical University,
[17]	Zhan Hui . . Journal of Kunming Medical University,
[18]	Jiang Chao Wu . . Journal of Kunming Medical University,
[19]	. Study on the Expression of CD45RO+ and CD45RA+T Lymphocytes in Peripheral Blood of Children Patients with Infectious Mononucleosis. Journal of Kunming Medical University,
[20]	Huang Ying . The Research of Mouse Bone Marrow-derived Mesenchymal Stem Cells Culture Condition in vitro. Journal of Kunming Medical University,